Published in Clin Cancer Res on August 01, 2008
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74
Epidemiology and risk factors for kidney cancer. Nat Rev Urol (2010) 5.25
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol (2013) 4.24
Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature (2014) 3.80
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Contemporary epidemiology of renal cell cancer. Cancer J (2008) 2.40
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2011) 2.05
Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nat Med (2017) 2.02
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. Int J Cancer (2013) 1.71
Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol (2014) 1.65
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol (2010) 1.55
Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J Exp Clin Cancer Res (2013) 1.50
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49
The VHL-dependent regulation of microRNAs in renal cancer. BMC Med (2010) 1.46
Renal cell carcinoma. BMJ (2014) 1.45
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet (2011) 1.43
Human health effects of trichloroethylene: key findings and scientific issues. Environ Health Perspect (2012) 1.34
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res (2013) 1.31
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep (2009) 1.25
Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Res (2015) 1.24
Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med (2010) 1.14
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol (2012) 1.14
Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res (2011) 1.12
SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell (2014) 1.11
LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. PLoS One (2011) 1.11
microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One (2012) 1.11
Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol (2010) 1.11
Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene (2011) 1.10
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res (2013) 1.10
Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene (2014) 1.09
The metabolic basis of kidney cancer. Semin Cancer Biol (2012) 1.09
Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08
The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma. Hum Mol Genet (2011) 1.08
Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med Genomics (2010) 1.06
Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome. Nat Rev Urol (2015) 1.04
Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res (2013) 1.04
Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer (2009) 1.03
PHD2 in tumour angiogenesis. Br J Cancer (2010) 1.02
New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease. Clin Cancer Res (2015) 0.98
Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci U S A (2014) 0.97
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene (2009) 0.96
Racial difference in histologic subtype of renal cell carcinoma. Cancer Med (2013) 0.96
Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States. PLoS One (2013) 0.94
Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Pathol (2015) 0.94
Validation of housekeeping gene and impact on normalized gene expression in clear cell renal cell carcinoma: critical reassessment of YBX3/ZONAB/CSDA expression. BMC Mol Biol (2014) 0.93
SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol (2014) 0.93
VHL type 2B mutations retain VBC complex form and function. PLoS One (2008) 0.93
miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget (2015) 0.93
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol (2014) 0.92
Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat (2013) 0.92
Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol (2013) 0.91
The PI3K/AKT Pathway and Renal Cell Carcinoma. J Genet Genomics (2015) 0.90
Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications. Nat Protoc (2013) 0.89
Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89
Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hypertension (2014) 0.89
Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma. Front Oncol (2012) 0.88
Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One (2010) 0.88
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene (2011) 0.85
Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis. J Thyroid Res (2011) 0.85
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther (2014) 0.85
Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS One (2014) 0.85
Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma. Oncotarget (2012) 0.85
Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Clin Cancer Res (2016) 0.85
Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule. Sci Rep (2013) 0.85
GPC3 reduces cell proliferation in renal carcinoma cell lines. BMC Cancer (2014) 0.84
Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun (2014) 0.84
RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res (2014) 0.84
The genetic basis of pheochromocytoma and paraganglioma: implications for management. Urology (2014) 0.83
Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays. PLoS One (2011) 0.83
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res (2014) 0.83
Choosing the right cell line for renal cell cancer research. Mol Cancer (2016) 0.82
Renal cell neoplasms contain shared tumor type-specific copy number variations. Am J Pathol (2012) 0.81
Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma. Int J Oncol (2012) 0.81
The genetic basis of kidney cancer: implications for management and use of targeted therapeutic approaches. Eur Urol (2012) 0.81
Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med (2014) 0.81
High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget (2015) 0.81
The epigenetic landscape of renal cancer. Nat Rev Nephrol (2016) 0.81
TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol (2015) 0.80
Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma. Oncotarget (2014) 0.80
Epigenetic silencing of Na,K-ATPase β 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma. Epigenetics (2014) 0.80
The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol (2016) 0.80
HIF1α and HIF2α exert distinct nutrient preferences in renal cells. PLoS One (2014) 0.80
Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma. PLoS One (2016) 0.80
Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis. J Cancer (2011) 0.79
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol (2015) 0.79
Single nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinoma. PLoS One (2013) 0.79
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet (2002) 8.19
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
Mutation detection using Surveyor nuclease. Biotechniques (2004) 3.72
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev (2002) 2.36
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res (2006) 1.91
Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. J Biol Chem (1994) 1.72
Purification, cloning, and characterization of the CEL I nuclease. Biochemistry (2000) 1.68
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res (2000) 1.58
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol (2002) 1.48
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res (1988) 1.48
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer (2005) 1.41
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int (2006) 1.34
Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma. J Urol (2002) 1.03
Mutational state of von Hippel-Lindau and adenomatous polyposis coli genes in renal tumors. Oncology (1997) 0.97
Random mutagenesis-PCR to introduce alterations into defined DNA sequences for validation of SNP and mutation detection methods. Hum Mutat (2001) 0.93
Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. Genes Chromosomes Cancer (2002) 0.93
Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent) (2007) 0.92
Improved detection of allele loss in renal cell carcinomas after removal of leukocytes by immunologic selection. J Natl Cancer Inst (1989) 0.89
Is the P25L a "real" VHL mutation? Mol Diagn (2001) 0.88
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
International network of cancer genome projects. Nature (2010) 20.35
Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst (2004) 19.00
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med (2013) 7.30
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol (2005) 6.44
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
von Hippel-Lindau disease. Lancet (2003) 6.20
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 6.00
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ (2009) 5.79
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst (2012) 5.27
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet (2005) 5.01
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. Am J Respir Crit Care Med (2010) 4.35
Hematotoxicity in workers exposed to low levels of benzene. Science (2004) 4.19
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet (2009) 4.01
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet (2007) 3.84
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
Mutation detection using Surveyor nuclease. Biotechniques (2004) 3.72
International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control (2008) 3.72
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
Listing occupational carcinogens. Environ Health Perspect (2004) 3.57
Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies. Int J Epidemiol (2008) 3.56
A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet (2010) 3.53
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ (2005) 3.48
SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res (2004) 3.47